Conclusion. In this limited population, it appears FMT may predispose to weight gain, which may reflect improved health with CDI cure. However, effects of FMT on patient’s microbiome must also be considered. As this intervention becomes more widely used we must be increasingly aware of possible metabolic side effects and ensure documentation of weight changes as part of FMT protocols.

Disclosures. All authors: No reported disclosures.

126. Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
Teresa Khalil MD1; Zachary Flechner, MD2; Robert Chow, MD2; Melinda Monteforte, PharmD3 and Luis A. Marcus, MD, MPH1; Infectious Disease, Stony Brook University Hospital, Stony Brook, New York; Internal Medicine, Stony Brook University Hospital, Stony Brook, New York; Infectious Diseases, Stony Brook University Hospital, Stony Brook, New York; Pharmacy Department, Stony Brook University Hospital, Stony Brook, New York.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Fidaxomicin is a narrow spectrum macrocyclic antibiotic used for the treatment of Clostridium difficile infection (CDI). The objective of this study is to compare the recurrence and mortality rates of patients with CDI who received either vancomycin or fidaxomicin at Stony Brook University Hospital.

Methods. A retrospective chart review was performed to identify all hospitalized patients who received fidaxomicin and vancomycin for the period 2011-2015. Inclusion criteria included patient age ≥18 years, stool positive PCR test for C. difficile and being treated 20 days of either fidaxomicin or vancomycin orally. Clinical recurrence was defined as a return of diarrhea, a positive test for C. difficile toxin B and a need for retreatment for CDI within 90 days of cessation of therapy.

Results. A total of 55 (52.7% male) and 74 (51.4% male) cases met inclusion criteria. In the fidaxomicin group, 16 patients had severe events, including age was 65.9 ± 1.88 and 63.7 ± 1.86 years in group F and V respectively (P = 0.4). Median length of hospitalization was 14 and 9 days for F and V respectively (P = 0.6). Both groups had similar proportions on the following variables: immunosuppression (V 36.5% vs. F 36.4%, P = 0.9), ≥ 1 prior episode of CDI (V 59.5% vs. F 61.8%, P = 0.8), sepsis on admission (V 29.7%, F 36.4%, P = 0.4), the use of any antibiotic during the last 30 days (V 74.3%, 71%, P = 0.7), and treatment with additional anti-CDI therapy (V 24.3%, F 29.1%; P = 0.5). CDI recurrence rate was 24% (V) and 40% (F; P = 0.057). The 90-day mortality rate was 4.1% in the vancomycin group and 10.9% in the fidaxomicin group (P = 0.13).

Conclusion. Fidaxomicin had a higher recurrent CDI than vancomycin in this tertiary medical center.

Disclosures. All authors: No reported disclosures.

126. Factors Affecting Effectiveness of Fecal Microbiota Transplant
Danielle Mooby, MPH; Patty Mcgraw, RN, MS; Chad Duffalo, MD, MPH; Marci Drees, MD, MS; Fedele Depalma, MD; Christine Herdman, MD; Scott Myers, MD and Alfred E. Bacon III, MD, Christiana Care Health System, Newark, Delaware.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Fecal microbiota transplant (FMT) is an effective treatment for relapsing Clostridium difficile infection (CDI). With more widespread use of this intervention, variable cure rates (70-95%) have been observed. We conducted this study to identify specific patient- and procedure-level factors affecting FMT effectiveness, hypothesizing that those patients with higher comorbidity, inadequate bowel preparation, and retention time did not predict FMT failure. Future studies should include larger patient populations (50+ yrs. old) and use a more complex index to define failure.

Methods. A retrospective chart review was performed to identify all FMT patients into a registry and followed them regularly for up to 1 year, hypothesizing that those patients with higher comorbidity, inadequate bowel preparation, and retention time did not predict FMT failure. We used 1-sided t-tests to test our hypotheses.

Results. During the study period, 41 patients (mean age 65 yrs, SD 17.6 yrs) underwent FMT. Most (37, 90%) were performed via colonoscopy, 1 via upper endoscopy, and 3 via oral preparation (capsules). FMT failure occurred in 10 patients (24.4%). Of the 20 relapse events, 16 had comorbid conditions, 2 had no current comorbid conditions, and 3 were lost to follow-up. Patients with higher Charlson scores failed more frequently (P = 0.04), and history of tumor (P = 0.03) and pulmonary disease (P = 0.04) were both associated with failure. No other factors, including age, retention time, and Boston bowel prep score, were associated with failure.

Conclusion. This study found that patients with multiple comorbid conditions, as defined by the Charlson index, are at risk for FMT failure. However, quality of bowel prep and retention time did not predict FMT failure. Future studies should include larger samples of FMT patients to determine whether specific comorbidities such as history of tumor and pulmonary disease are clinically significant predictors of FMT failure.

Disclosures. All authors: No reported disclosures.

126.4. Cost Effectiveness Analysis of Fecal Transplant Delivery Methods for Recurrent Clostridium difficile Infections in Outpatients
Jostina Walker, MD1; Nathan F. Cornelio, MD, FIDSA2; Santiago Vazquez, MD, FIDSA3 and Ellen Eaton, MD4; Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama; Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Clostridium difficile infection (CDI) affects more than 1 million annually in US health care settings. Recurrent CDI (RCDI, recurrence within 8 weeks of initial treatment) contributes substantially to this cost. The objective was to compare the cost-effectiveness of FMT delivered via colonoscopy vs. blind nasogastric tube (NGT) in outpatients. We hypothesized that FMT by NGT would be cost-effective given its low risk and simplicity.

Methods. A decision-analytic simulation model compared the cost-effectiveness of FMT by colonoscopy vs. NGT from a third-party payer perspective. Our base case cure rates were derived from a cohort receiving outpatient RCDI treatment at our institution. Cure was defined as resolution of symptoms for ≥ 90 days. Procedural cost and consultation was defined by average reimbursement to a large southeastern medical center in 2016 USD based on current procedural terminology (CPT) codes, and cost of disease states were derived from published literature. Healthcare costs were defined by quality of life year (QALY) based on published literature. Incremental Cost Effectiveness ratio (ICER) was defined as the cost per additional QALY gained. We assumed a 90 day time horizon. One-way sensitivity analysis was performed on all variables using ranges defined by published literature. We used TreeAge Software (Williamstown, MA).

Results. In the base case, FMT by colonoscopy was dominant (more effective and less costly) than NGT, with cost of $1,568/QALY vs. $1,910/QALY respectively. Cure rates of FMT by colonoscopy vs. NGT (100% vs. 87%) had the largest impact on ICER based on one-way sensitivity analysis. Therefore, a subsequent two-way sensitivity analysis was conducted to compare cure rates of both delivery methods and found that NGT delivery is cost effective as cure rates approach colonoscopy cure delivery cure rates within 5 percentage points.

Conclusion. Contrary to our hypothesis, our decision model supports FMT by colonoscopy as the preferred delivery method in outpatients with RCDI relative to NGT delivery. Additional costs of colonoscopy delivery are off-set by the improved cure rate leading to lower overall costs. As cure rates from NGT delivery are optimized, NGT may become the preferred FMT delivery method.

Disclosures. All authors: No reported disclosures.

126.5. Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea
Eduardo Yepez Guevara, MD1; Harika Yalamanchili, MD2; Andrew Chao, MD3; Kevin Gary, PharmD, M.S7, Michal Bhatti, MD, PhD7; Samuel L. Atkin, PharmD8 and Pablo C. Okhyuesen, MD, FACP, FIDSA9; Infectious Diseases, University of Texas Health Science Center at Houston – MD Anderson Cancer Center, Houston, Texas; Infectious Disease, Texas Infectious Disease, Baycollege Medical – MD Anderson Cancer Center, Houston, Texas; University of Houston College of Pharmacy, Houston, Texas; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas; Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Session: 148. C. difficile: From the Bench to Bedside
Friday, October 6, 2017: 12:30 PM

Background. Cancer patients are at increased risk for Clostridium difficile infection (CDI) due to frequent health care contact, chemotherapy, use of antibiotics, and immunosuppression. Distinct ribotypes are associated with CDI adverse outcomes. Here we categorized patients into one of the 20 most prevalent ribotypes in our hospital. We examined the contribution of C. difficile ribotypes to CDI severity, response to therapy and outcomes in this population.

Methods. Demographic and clinical data were collected from 90 cancer patients with a first episode or first recurrence of CDI identified by two-step PCR followed by EIA for A/B toxins. Fluorescent PCR ribotyping (FPCR) was performed on fecal isolates. We identified 27 distinct ribotypes between October 2016 and January 2017. Clinical outcomes were studied in three FPCR subgroups. Group I (GI, n = 27) included 10 (37%) GI I1 (II, GI1 n = 17) included virulent types 002, 027, 078; 126, 244 and group II (GI, n = 46) included the rest. Treatment failure was defined as no response after at least 3 days of a CDI treatment regimen. CDI severity was determined using Zar’s criteria, presence of bacteremia and ICU stay.

Results. The proportion of patients ≥50 yrs. old, with healthcare onset CDI (31%), primary CDI (92.2%), and on active chemotherapy (70%) was similar across all patients.